Recorded Presentation from the NCCN Oncology Case Manager and Medical Director Program: Updates in the Treatment of HER-2 Positive Breast Cancer
It is important for clinicians to be aware of the updated criteria to appropriately select patients who are sensitive to HER2-targeted agents; to stay up-to-date with evolving treatment strategies; to understand how to choose optimal treatment based on patient preference, toxicities, and drug availability; and to effectively evaluate patients during therapies and manage any therapy-related adverse effects.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Kidney Cancer
For patients with advanced RCC, several factors are taken into consideration to help determine which systemic regimen to consider in the first-line and subsequent line therapy. It is important for clinicians to understand when to use regimens for their patient’s unique clinical situation and how to treatment for patients with metastatic RCC requiring second, third, fourth, or further lines of therapy.
Category
  • Kidney Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Endometrial Cancer
Minimally invasive surgical techniques for endometrial cancers, particularly robotic-assisted laparoscopy, have been shown to decrease surgical morbidity and improve 30-day postoperative outcomes for appropriately selected patients with endometrial cancer. Despite evidence of improved outcomes, disparities persist in awareness of and access to minimally invasive surgery.
Category
  • Women's Health Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Recorded Presentation from the NCCN Oncology Case Manager and Medical Director Program: Updates in the Treatment of Follicular Lymphoma and Diffuse Large B-Cell Lymphomas
Case managers and medical directors are challenged to maintain a high awareness of the recent therapeutic advances in the management of FL and DLBCL in order to develop an efficient coordinated treatment approach that incorporates novel therapies in the appropriate patient population.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Recorded Presentation from the NCCN Oncology Case Manager and Medical Director Program: Supportive Care of Hematopoietic Cell Transplant Patients
Although considerable progress has been made in identifying supportive care issues in HCT survivors, large, prospective trials demonstrating the effectiveness of supportive care interventions for HCT-related complications are needed to guide future development of evidence-based guidelines. Importantly, because long-term HCT recipients may no longer be followed by transplant centers, recommendations for supportive care should be geared toward community healthcare providers who may not routinely care for HCT recipients.
Category
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • ASWB continuing education credit
  • CCM clock hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Non-Melanoma Skin Cancer
Clinician and patient education is critical for safe administration of checkpoint immunotherapies and screening to identify patients who are not suitable candidates for checkpoint inhibitor therapy.
Category
  • Non-Melanoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Biomarker Testing in Non-Small Cell Lung Cancer
New targeted therapy and immunotherapy regimens are frequently approved and added to the NCCN Guidelines® Non-Small Cell Lung Cancer. Newer testing methods are being developed for patients who are not medically fit for invasive testing. Oncologists should be familiar with the current biomarker testing recommendations to improve outcomes for their patients with metastatic NSCLC.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Smoking Cessation in Patients with Cancer
Providing care for patients with cancer who smoke poses unique challenges for oncology teams already managing a complex disease, and standardized guidance on effective smoking cessation interventions for patients with cancer is needed. NCCN recommends evidence-based approaches to pharmacotherapy and behavior therapy in order to help primary oncology teams to provide cessation support tailored to their patients’ needs.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Radiation Techniques in the Treatment of Lung Cancer
Multidisciplinary evaluations of patients with non-small cell lung cancer (NSCLC) should include radiation oncologists, because radiation therapy (RT) has a potential role in all stages of NSCLC.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
New Targeted Therapies for Non-Small Cell Lung Cancer
The NCCN Guidelines® Non-Small Cell Lung Cancer are updated frequently throughout the year to include new approved agents and indications. It is difficult for clinicians to stay up-to-date on the most recent recommendations to improve outcomes for their patients with metastatic NSCLC. In addition, clinicians need to be aware of novel adverse reactions that may occur with the new targeted therapies.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation

Pages